GPC Lifesciences has evolved largely through long-standing professional relationships built over decades in the pharmaceutical industry
Dr. PC Ray, Director & CEO
The pharmaceutical industry today is being shaped by a new set of priorities—building resilient supply chains, developing cost-efficient manufacturing processes, strengthening regulatory compliance, and accelerating the commercialization of complex active pharmaceutical ingredients (APIs).
While India has established itself as one of the world's largest producers of generic medicines, the industry continues to face critical challenges in process innovation, technology development, and reducing dependence on imported intermediates and specialty chemicals.
Recognizing these industry needs, GPC Lifesciences was founded in 2020 as a research-driven API technology development company committed to transforming laboratory science into commercially viable manufacturing solutions.
Led by pharmaceutical R&D veteran Dr. P. C. Ray, whose career spans more than three decades across leading pharmaceutical organizations, the company specializes in developing scalable, regulatory-compliant, and cost-effective API processes that enable pharmaceutical manufacturers to accelerate product development while strengthening India's journey towards pharmaceutical self-reliance.
Built on More than Three Decades of Pharmaceutical R&D
Dr. P. C. Ray's journey spans over 35 years across some of India's leading pharmaceutical organizations, including Ranbaxy Laboratories, Matrix Laboratories (later Mylan), GVK Bio, Lupin Pharmaceuticals, Arene Lifesciences and an API manufacturing company where he served as Chief Scientific Officer before launching GPC Lifesciences.
Throughout his career, he witnessed the remarkable transformation of pharmaceutical research - from an era of highly confidential process development and limited scientific databases to today's digitally connected and highly regulated global pharmaceutical ecosystem.
Working across regulated markets such as the United States, Japan, Australia, and Canada, Dr. Ray gained extensive experience in API process development, technology transfer, commercialization, and regulatory-driven manufacturing. These experiences ultimately shaped the vision behind GPC Lifesciences.
Rather than creating another API manufacturing company, the objective was to build an organization dedicated to solving one of the industry's most pressing challenges - developing robust manufacturing technologies that pharmaceutical companies can successfully commercialize.
GPC Lifesciences has evolved largely through long-standing professional relationships built over decades in the pharmaceutical industryDr. PC Ray, Director & CEO
Transforming Scientific Knowledge into Commercial Technology
Unlike conventional contract research organizations or manufacturers, GPC Lifesciences focuses exclusively on technology development. The company works closely with pharmaceutical manufacturers to understand their commercial objectives, regulatory requirements, quality expectations, and cost targets before designing optimized API manufacturing processes. Its expertise spans across custom process development for APIs, Process optimization and scale-up, Technology transfer, Commercialization support, Regulatory-oriented process design and Cost optimization for regulated and emerging markets.
“Every development program begins with understanding what the customer actually needs - not only scientifically but commercially. Whether the project involves anti-tuberculosis molecules, anti-diabetic APIs, or products intended for highly regulated markets such as Japan, the objective remains the same: deliver a manufacturing process that consistently meets quality expectations while remaining commercially competitive”, says Dr. PC Ray, Director and CEO.
Once the laboratory process is established, GPC Lifesciences supports technology transfer, pilot batches, validation activities, and manufacturing implementation, ensuring successful commercialization by its clients.
Addressing Industry Challenges Through Practical Innovation
One of the defining strengths of GPC Lifesciences is its practical, industry-first approach to research. According to Dr. Ray, “Successful API development requires much more than laboratory chemistry. Every process must eventually perform reliably under commercial manufacturing conditions while satisfying increasingly stringent global regulatory expectations. The company's projects are therefore designed around scalability, safety, process efficiency, raw material availability, and manufacturing economics”.
Another significant area of expertise involves designing alternative synthetic routes around existing process patents. For generic pharmaceutical manufacturers, product patents may expire before process patents, creating a narrow commercial window for market entry. Developing legally compliant alternative manufacturing routes requires extensive scientific knowledge, deep understanding of synthetic organic chemistry, and careful process engineering.
Leveraging decades of industrial experience, GPC Lifesciences helps pharmaceutical companies identify scientifically viable pathways that enable commercialization without infringing existing intellectual property.
Research Driven by Industry Needs
GPC Lifesciences has evolved largely through long-standing professional relationships built over decades in the pharmaceutical industry. Rather than pursuing technologies without defined applications, the company develops solutions based on real industrial requirements.
“This customer-centric approach has enabled GPC Lifesciences to expand beyond pharmaceuticals into adjacent chemical sectors. One notable engagement involved developing commodity chemical technologies for a petrochemical company seeking to reduce dependence on imported products. Although this represented an entirely new domain, the team invested months understanding the chemistry, industrial requirements, and commercial objectives before successfully developing the required technologies”, speaks Dr. GP Singh, Co-Founder and Director.
Expanding through Collaboration and Indigenous Innovation
Since its inception, GPC Lifesciences has largely been funded through founder investment and client-supported research projects. The company is actively pursuing government research grants to expand work in areas such as orphan drugs, anti-malarial therapies, and strategically important pharmaceutical technologies. It is also strengthening collaborations with academic institutions to accelerate translational research and bridge the gap between laboratory innovation and industrial commercialization.
Dr. Ray believes, “India possesses exceptional scientific talent but requires stronger industry-academia partnerships and more accessible innovation support mechanisms to fully realize its research potential. While government initiatives have significantly strengthened the startup ecosystem, experienced technology developers often require better platforms that facilitate collaboration, funding, and commercialization.”
Contributing to India's Pharmaceutical Self-Reliance
Drawing upon more than six decades of combined experience shared by its leadership team, GPC Lifesciences aims to become a trusted technology partner for pharmaceutical companies seeking efficient, scalable, and regulatory-compliant API processes.
By combining scientific expertise, commercial understanding, and process innovation, the company is helping manufacturers reduce technology dependence, accelerate product development, and strengthen India's position as a globally competitive pharmaceutical innovation hub. The company has also initiated collaborations with researchers associated with Pune's National Chemical Laboratory (NCL) ecosystem while recruiting young scientists with expertise in AI-assisted research tools.
For GPC Lifesciences, the mission extends beyond developing manufacturing processes. It is about building technologies that enable long-term pharmaceutical self-reliance, support affordable healthcare, and contribute meaningfully to the next generation of India's life sciences ecosystem.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")